Mycetoma

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:2583B47.0B47.1B47.9
Who is this for?
Show terms as
1Active trials7Specialists8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Mycetoma, also known as Madura foot or maduromycosis, is a chronic, progressive, and destructive subcutaneous infection caused by certain species of fungi (eumycetoma) or filamentous bacteria (actinomycetoma). It is classified as a neglected tropical disease by the World Health Organization. The disease typically affects the foot but can involve any part of the body, including the hands, back, and other extremities. It is acquired through traumatic inoculation of the causative organism into the skin, often via thorns, splinters, or other penetrating injuries. Mycetoma is most prevalent in tropical and subtropical regions, particularly in the so-called "mycetoma belt" stretching across Africa, the Middle East, and parts of Asia and Latin America. The hallmark clinical triad of mycetoma consists of a painless subcutaneous mass (tumefaction), multiple draining sinuses, and the discharge of grains (colonies of the causative organism). The disease progressively involves deeper tissues including fascia, muscle, and bone, leading to significant tissue destruction and deformity. If left untreated, it can cause severe disability and may necessitate amputation. The infection primarily affects the musculoskeletal system and skin. Secondary bacterial infections of the sinuses are common and can cause pain and systemic illness. Treatment depends on the causative agent. Actinomycetoma generally responds well to prolonged courses of combined antibiotic therapy, typically including trimethoprim-sulfamethoxazole with amikacin or other agents, administered for months to years. Eumycetoma is more challenging to treat and often requires prolonged antifungal therapy (such as itraconazole, voriconazole, or posaconazole) combined with surgical excision. In advanced cases with extensive bone involvement, amputation may be the only option. Early diagnosis and treatment are critical to improving outcomes and preventing disability.

Also known as:

Clinical phenotype terms— hover any for plain English:

Prominent superficial veinsHP:0001015Recurrent fungal infectionsHP:0002841Abnormal bone structureHP:0003330Recurrent bacterial skin infectionsHP:0005406Structural foot deformityHP:0010219Stiff skinHP:0030053Cobblestone-like hyperkeratosisHP:0031288Abnormal appendicular skeleton morphologyHP:0011844Cutaneous cystHP:0025245Abnormal forearm bone morphologyHP:0040072Abnormality of the lymphatic systemHP:0100763Abnormality of head or neckHP:0000152Painless fractures due to injuryHP:0002661
Age of Onset

Adult

Begins in adulthood (age 18 or older)

Orphanet ↗NORD ↗

FDA & Trial Timeline

1 event
Jun 2024Mycetoma Retrospective Data Collection

Drugs for Neglected Diseases

TrialRECRUITING

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

No FDA-approved treatments are currently listed for Mycetoma.

1 clinical trialare actively recruiting — trials can provide access to cutting-edge therapies.

View clinical trials →

Clinical Trials

1 recruitingView all trials with filters →
Other1 trial
Mycetoma Retrospective Data Collection
Actively Recruiting
PI: Doudou Sow, PhD (Université Gaston Berger) · Sites: Chandigarh; Dakar

Specialists

7 foundView all specialists →
AP
Ahmed Fahal, Prof
Specialist
PI on 1 active trial
DP
Doudou Sow, PhD
Specialist
PI on 1 active trial
SM
Shivaprakash M Rudramurthy, M.D
Specialist
PI on 1 active trial
MP
Mohamed Osman, PhD
Specialist
PI on 1 active trial
VD
Vishwananath gella, DM
Specialist
PI on 1 active trial
DM
Daniel E Barquero Orias, MD
Specialist
PI on 1 active trial
BM
Borna A Nyaoke, M.D
Specialist
PI on 1 active trial

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Mycetoma.

Search all travel grants →NORD Financial Assistance ↗

Community

Open MycetomaForum →

No community posts yet. Be the first to share your experience with Mycetoma.

Start the conversation →

Latest news about Mycetoma

Disease timeline:

New recruiting trial: Mycetoma Retrospective Data Collection

A new clinical trial is recruiting patients for Mycetoma

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Mycetoma

What is Mycetoma?

Mycetoma, also known as Madura foot or maduromycosis, is a chronic, progressive, and destructive subcutaneous infection caused by certain species of fungi (eumycetoma) or filamentous bacteria (actinomycetoma). It is classified as a neglected tropical disease by the World Health Organization. The disease typically affects the foot but can involve any part of the body, including the hands, back, and other extremities. It is acquired through traumatic inoculation of the causative organism into the skin, often via thorns, splinters, or other penetrating injuries. Mycetoma is most prevalent in trop

At what age does Mycetoma typically begin?

Typical onset of Mycetoma is adult. Age of onset can vary across affected individuals.

Are there clinical trials for Mycetoma?

Yes — 1 recruiting clinical trial is currently listed for Mycetoma on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.

Which specialists treat Mycetoma?

7 specialists and care centers treating Mycetoma are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.